| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Precigen (NASDAQ:PGEN) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.17, a high estimate of $14.00, and a low estimate of $6.00. This current average has increased by 29.07% from the previous average price target of $6.33.
The analysis of recent analyst actions sheds light on the perception of Precigen by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $6.00 | $6.00 |
| Benjamin Burnett | Stifel | Raises | Buy | $10.00 | $7.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $6.00 | $6.00 |
| Benjamin Burnett | Stifel | Maintains | Buy | $7.00 | - |
| Jason Butler | JMP Securities | Maintains | Market Outperform | $14.00 | - |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $6.00 | - |
For valuable insights into Precigen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Precigen analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Precigen's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -42.46% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Precigen's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2228.92%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Precigen's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -22.03%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Precigen's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -16.61%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Precigen adopts a prudent financial strategy, indicating a balanced approach to debt management.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PGEN
